NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Helfand M, Peterson K, Christensen V, et al. Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4 [Internet]. Portland (OR): Oregon Health & Science University; 2009 Jul.

Cover of Drug Class Review: Beta Adrenergic Blockers

Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4 [Internet].

Show details


Center for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews CRD Report Number 4. 2nd edition. 2001.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am. J. Prev. Med. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]
Potempa K, Babich K, Fruh S, Fogg L. Blood pressure and mood responses in hypertensive patients on antihypertensive medications. Journal of the American Academy of Nurse Practitioners. 1993;5(5):211–218. [PubMed: 8240880]
Paran E, Anson O, Neumann L. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients. Am. J. Hypertens. 1996;9(12 Pt 1):1206–1213. [PubMed: 8972892]
Walle PO, Westergren G, Dimenas E, Olofsson B, Albrektsen T. Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. J. Clin. Pharmacol. 1994;34(7):742–747. [PubMed: 7929868]
Omvik P, Lund-Johansen P, Haugland H. Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure. Cardiovascular Drugs & Therapy. 1993;7(1):125–132. [PubMed: 8097925]
Sundar S, Rajan AG, Somani PN, Kumar K. The effects of antihypertensive agents on the quality of life in Indian hypertensives. Acta Cardiol. 1991;46(2):227–235. [PubMed: 2048369]
Steiner SS, Friedhoff AJ, Wilson BL, Wecker JR, Santo JP. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J. Hum. Hypertens. 1990;4(3):217–225. [PubMed: 2194029]
Foerster EC, Greminger P, Siegenthaler W, Vetter H, Vetter W. Atenolol versus pindolol: side-effects in hypertension. Eur. J. Clin. Pharmacol. 1985;28(Suppl):89–91. [PubMed: 4054195]
Fogari R, Zoppi A, Corradi L, Preti P, Mugellini A, Lusardi P. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 1999;33(4):534–539. [PubMed: 10218722]
Lithell H, Selinus I, Hosie J, Frithz G, Weiner L. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. Eur. Heart J. 1987;8(Suppl M):55–64. [PubMed: 2967186]
Anonymous. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304(6824):405–412. [PMC free article: PMC1995577] [PubMed: 1445513]
Anonymous. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. British Medical Journal Clinical Research Edition. 1985;291(6488):97–104. [PMC free article: PMC1416260] [PubMed: 2861880]
Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. JAMA. 1988;259(13):1976–1982. [PubMed: 3346979]
Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903–1907. [PubMed: 9634263]
Anonymous. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255–3264. [PubMed: 2046107]
Furberg CD, Wright JT Jr, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA. 2002;288(23):2981–2997. [PubMed: 12479763]
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA. 2003;289(19):2560–2572. [PubMed: 12748199]
Yilmaz MB, Erdem A, Yalta K, Turgut OO, Yilmaz A, Tandogan I. Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Advances in Therapy. 2008 Sep;25(9):871–883. [PubMed: 18758699]
Blumenthal JA, Madden DJ, Krantz DS, et al. Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension. Clinical Pharmacology & Therapeutics. 1988;43(4):429–435. [PubMed: 3356086]
Buhler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS) J. Cardiovasc. Pharmacol. 1986;8(Suppl 11):S122–127. [PubMed: 2439782]
Dahlof C, Almkvist G, Dimenas E, et al. No difference in general well-being during antihypertensive treatment with atenolol or metoprolol CR. Annals of Clinical Research. 1988;20(Suppl 48):42–50. [PubMed: 3250317]
Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RHG. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clinical & Experimental Pharmacology & Physiology. 2007 Apr;34(4):327–331. [PubMed: 17324145]
Oberman A, Wassertheil-Smoller S, Langford HG, et al. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann. Intern. Med. 1990;112(2):89–95. [PubMed: 1967210]
Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann. Intern. Med. 1991;114(8):613–620. [PubMed: 2003706]
Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am. J. Hypertens. 1992;5(1):37–44. [PubMed: 1736933]
Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. Am. J. Med. 2000;108(5):359–365. [PubMed: 10759091]
Grant RH, Keelan P, Kernohan RJ, Leonard JC, Nancekievill L, Sinclair K. Multicenter trial of propranolol in angina pectoris. Am. J. Cardiol. 1966 Sep;18(3):361–365. [PubMed: 4958811]
Bongers V, Sabin GV. Comparison of the effect of two metoprolol formulations on total ischaemic burden. Clinical Drug Investigation. 1999;17(2):103–110.
Choong CY, Roubin GS, Harris PJ, et al. A comparison of the effects of beta-blockers with and without intrinsic sympathomimetic activity on hemodynamics and left ventricular function at rest and during exercise in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 1986;8(3):441–448. [PubMed: 2425156]
Comerford MB, Besterman EM. An eighteen months' study of the clinical response to metoprolol, a selective beta1-receptor blocking agent, in patients with angina pectoris. Postgrad. Med. J. 1976;52(610):481–486. [PMC free article: PMC2496449] [PubMed: 10564]
Comerford MB, Besterman EM. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension. Annals of Clinical Research. 1982;14(1):27–31. [PubMed: 7137874]
Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur. J. Clin. Pharmacol. 1986;31(2):143–147. [PubMed: 2879733]
Koch G, Fransson L. Hemodynamic effects at rest and during exercise of combined alpha/beta-receptor blockade and of beta-receptor blockade alone in patients with ischemic heart disease. J. Cardiovasc. Pharmacol. 1987;10(4):474–478. [PubMed: 2444802]
Koch G, Fransson L. Hemodynamic and adrenergic effects of combined alpha/beta-receptor blockade versus combined beta-receptor and slow channel calcium blockade in patients with ischemic heart disease. Int. J. Cardiol. 1989;25(1):73–79. [PubMed: 2793265]
Nyberg G, Bjuro T, Hagman M, Smith U. Relation between ST-depression and chest pain in patients with coronary heart disease receiving no treatment and after beta-blockade and combined alpha-beta-blockade. Acta Medica Scandinavica Supplementum. 1981;644:30–33. [PubMed: 6941640]
Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag. 2007;3(2):235–242. [PMC free article: PMC1994030] [PubMed: 17580734]
Frishman W, Kostis J, Strom J, et al. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am. Heart J. 1979;98(4):526–535. [PubMed: 39447]
Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Am. J. Cardiol. 1990;65(9):577–582. [PubMed: 2178381]
Destors JM, Boissel JP, Philippon AM, Schbath J. Controlled clinical trial of bepridil, propranolol and placebo in the treatment of exercise induced angina pectoris. B.I.S. Fundamental & Clinical Pharmacology. 1989;3(6):597–611. [PubMed: 2515136]
Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927–1936. [PubMed: 10349897]
Stephenson LW, MacVaugh HI, Tomasello DN, Josephson ME. Propranolol for prevention of postoperative cardiac arrhythmias: A randomized study. Ann. Thorac. Surg. 1980;29(2):113–116. [PubMed: 6965579]
Connolly SJ, Cybulsky I, Lamy A, et al. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The β-Blocker Length Of Stay (BLOS) study. American Heart Journal. 2003;145(2):226–232. [PubMed: 12595838]
Jakobsen CJ, Bille S, Ahlburg P, Rybro L, Hjortholm K, Andresen EB. Perioperative metoprolol reduces the frequency of atrial fibrillation after thoracotomy for lung resection. Journal of Cardiothoracic & Vascular Anesthesia. 1997;11(6):746–751. [PubMed: 9327317]
Matangi MF, Strickland J, Garbe GJ, et al. Atenolol for the prevention of arrhythmias following coronary artery bypass grafting. Can. J. Cardiol. 1989;5(4):229–234. [PubMed: 2659151]
Lamb RK, Prabhakar G, Thorpe JA, Smith S, Norton R, Dyde JA. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur. Heart J. 1988;9(1):32–36. [PubMed: 3257915]
Anonymous. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. Eur. Heart J. 1995;16(12):1825–1832. [PubMed: 8682014]
Anonymous. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981;304(14):801–807. [PubMed: 7010157]
Boissel JP, Leizorovicz A, Picolet H, Ducruet T. Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators. Am. J. Cardiol. 1990;66(9):24C–31C. [PubMed: 2220646]
Hansteen V, Moinichen E, Lorentsen E, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. British Medical Journal Clinical Research Ed. 1982;284(6310):155–160. [PMC free article: PMC1495539] [PubMed: 6799077]
Salathia KS, Barber JM, McIlmoyle EL, et al. Very early intervention with metoprolol in suspected acute myocardial infarction. Eur. Heart J. 1985;6(3):190–198. [PubMed: 3896811]
Rehnqvist N, Olsson G. Influence of ventricular arrhythmias by chronic post infarction treatment with metoprolol [abstract] Circulation. 1983;68(Suppl 3):69.
Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchell JR. Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br. Med. J. 1980;280(6218):885–888. [PMC free article: PMC1601074] [PubMed: 6992916]
Johnson JM, Yen TC, Zhao K, Kosiba WA. Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1573–1579. [PubMed: 15576441]
Mrdovic IB, Savic LZ, Perunicic JP, et al. Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. Am. Heart J. 2007 Jul;154(1):116–122. [PubMed: 17584563]
Jonsson G, Abdelnoor M, Muller C, Kjeldsen SE, Os I, Westheim A. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. Cardiology. 2005;103(3):148–155. [PubMed: 15785019]
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog. Cardiovasc. Dis. 1985;27(5):335–371. [PubMed: 2858114]
Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am. J. Cardiol. 1997;80(9B):35J–39J. [PubMed: 9375948]
Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730–1737. [PMC free article: PMC31101] [PubMed: 10381708]
Basu S, Senior R, Raval U, Van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: A placebo-controlled, randomized trial. Circulation. 1997;96(1):183–191. [PubMed: 9236433]
Anonymous. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–1390. [PubMed: 11356434]
Fonarow GC, Lukas MA, Robertson M, Colucci WS, Dargie HJ. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) Am. Heart J. 2007 Oct;154(4):637–644. [PubMed: 17892984]
Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. European Journal of Heart Failure. 2000;2(3):333–340. [PubMed: 10938496]
Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73(3):503–510. [PubMed: 3948357]
Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial) Am. J. Cardiol. 1997;80(9B):40J–44J. [PubMed: 9375949]
Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am. J. Cardiol. 1990;66(3):251–260. [PubMed: 2195860]
Anonymous. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247(12):1707–1714. [PubMed: 7038157]
Roque F, Amuchastegui LM, Lopez Morillos MA, et al. Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction. Circulation. 1987;76(3):610–617. [PubMed: 3304706]
McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J. Am. Coll. Cardiol. 2005 Feb 15;45(4):525–530. [PubMed: 15708698]
Manger Cats V, van Capelle FLJ, Lie KJ, Durrer D. The Amsterdam metoprolol trial. Effect of treatment with metoprolol on first year mortality in a single center study with low placebo mortality rate after myocardial infarction. [abstract] Drugs. 1985;29(Suppl 1):8.
Anonymous. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J. 1983;4(6):367–375HH. [PubMed: 6617682]
Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur. Heart J. 2005 Feb;26(3):215–225. [PubMed: 15642700]
Doughty RN, Sharpe N. Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. Annu. Rev. Med. 1997;48:103–114. [PubMed: 9046949]
Avezum A, Tsuyuki RT, Pogue J, Yusuf S. Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. Can. J. Cardiol. 1998;14(8):1045–1053. [PubMed: 9738164]
Zarembski DG, Nolan PE Jr, Slack MK, Lui CY. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemic dilated cardiomyopathy. Am. J. Cardiol. 1996;77(14):1247–1250. [PubMed: 8651108]
Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 1997;30(1):27–34. [PubMed: 9207617]
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98(12):1184–1191. [PubMed: 9743509]
Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. Ann. Intern. Med. 2001;134(7):550–560. [PubMed: 11281737]
Lee S, Spencer A. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J. Fam. Pract. 2001;50(6):499–504. [PubMed: 11401736]
Bouzamondo A, Hulot JS, Sanchez P, Cucherat M, Lechat P. Beta-blocker treatment in heart failure. Fundamental & Clinical Pharmacology. 2001;15(2):95–109. [PubMed: 11468019]
Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. European Journal of Heart Failure. 2000;2(4):407–412. [PubMed: 11113718]
Anonymous. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994;90(4):1765–1773. [PubMed: 7923660]
Anonymous. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. [PubMed: 10023943]
Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94(11):2807–2816. [PubMed: 8941106]
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 1996;334(21):1349–1355. [PubMed: 8614419]
Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical pregression in patients with mild symptoms of heart failure. Circulation. 1996;94(11):2800–2806. [PubMed: 8941105]
Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. J. Card. Fail. 1997;3(3):173–179. [PubMed: 9330125]
Anonymous. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997;349(9049):375–380. [PubMed: 9033462]
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001;344(22):1651–1658. [PubMed: 11386263]
Cleland JGF, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14–21. [PubMed: 12853194]
Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am. Heart J. 2004;147(2):324–330. [PubMed: 14760332]
Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J. Am. Coll. Cardiol. 2003;41(9):1438–1444. [PubMed: 12742278]
Fowler MB. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial: Carvedilol in severe heart failure. Am. J. Cardiol. 2004;93(9 SUPPL 1):35B–39B. [PubMed: 15144935]
Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342(8885):1441–1446. [PubMed: 7902479]
Waagstein F, Stromblad O, Andersson B, et al. Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: A randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. European Journal of Heart Failure. 2003;5(5):679–691. [PubMed: 14607208]
Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 2001;353(9169):2001–2007. [PubMed: 10376614]
Anonymous. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000;101(4):378–384. [PubMed: 10653828]
Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. European Journal of Heart Failure. 2005 Jun;7(4):631–639. [PubMed: 15921805]
Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J. Am. Coll. Cardiol. 2001;38(4):932–938. [PubMed: 11583861]
Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999;353(9169):2001–2007. [PubMed: 10376614]
Dungen H-D, Apostolovic S, Inkrot S, et al. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clinical Research in Cardiology. 2008 Sep;97(9):578–586. [PubMed: 18542839]
Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99(20):2645–2651. [PubMed: 10338457]
Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102(5):546–551. [PubMed: 10920067]
Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. 2002;40(7):1248–1258. [PubMed: 12383572]
Sanderson JE, Chan SK, Yip G, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J. Am. Coll. Cardiol. 1999;34(5):1522–1528. [PubMed: 10551702]
Poole-Wilson P, Swedberg K, Cleland J, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13. [PubMed: 12853193]
Poole-Wilson PA, Cleland JG, Di Lenarda A, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. European Journal of Heart Failure. 2002;4(3):321–329. [PubMed: 12034158]
Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. Am. Heart J. 2005;149(2):370–376. [PubMed: 15846279]
Cleland JG, Charlesworth A, Lubsen J, et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET) J. Am. Coll. Cardiol. 2006;47(8):1603–1611. [PubMed: 16630997]
Remme WJ, Torp-Pedersen C, Cleland JGF, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J. Am. Coll. Cardiol. 2007 Mar 6;49(9):963–971. [PubMed: 17336720]
Lombardo RMR, Reina C, Abrignani MG, Rizzo PA, Braschi A, De Castro S. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. American Journal of Cardiovascular Drugs. 2006;6(4):259–263. [PubMed: 16913827]
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–1587. [PubMed: 10821361]
Katritsis DG, Panagiotakos DB, Karvouni E, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am. J. Cardiol. 2003;92(9):1116–1119. [PubMed: 14583369]
Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J. Am. Coll. Cardiol. 2000;36(1):139–146. [PubMed: 10898425]
Kuhlkamp V. Metoprolol verses Placebo in the recidive prophylaxis after cardioversion of atrial fibrillation. Z. Kardiol. 1998;87(Suppl 1)
Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol Alone or in Combination with Digoxin for the Management of Atrial Fibrillation in Patients with Heart Failure? J. Am. Coll. Cardiol. 2003;42(11):1944–1951. [PubMed: 14662257]
Gerber WD, Diener HC, Scholz E, Niederberger U. Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis. Cephalalgia. 1991;11(1):37–45. [PubMed: 2036669]
Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia. 1984;4(2):91–96. [PubMed: 6428749]
Olsson JE, Behring HC, Forssman B, et al. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. Acta. Neurol. Scand. 1984;70(3):160–168. [PubMed: 6391066]
Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Upsala Journal of Medical Sciences - Supplement. 1980;31:37–40. [PubMed: 7006182]
Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine. Cephalalgia. 1982;2(3):165–170. [PubMed: 6758949]
Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs.propranolol vs. placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta. Neurol. Scand. 1984;69(1):1–8. [PubMed: 6367336]
Worz R, Reinhardt-Benmalek B, Grotemeyer KH, Foh M. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura - A randomized double-blind cross-over multicenter study. Cephalalgia. 1991;11(SUPPL 11):152–153.
Worz R, Reinhardt-Benmalek B, Foeh M, Grotemeyer KH, Scharafinski HW. Migraine prophylaxis with bisoprolol. Headache Quarterly. 1992;3(1):64–72.
Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache. 2008 Jan;48(1):118–125. [PubMed: 18184294]
Linde K, Rossnagel K. Propranolol for migraine prophylaxis [Systematic Review] Cochrane Database of Systematic Reviews. 2007;1:1.
Forssman B, Lindblad GJ, Zborkinova V. Atenolol for migraine prophylaxis. Headache. 1983;23:188–190. [PubMed: 6350226]
van de Ven LL, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia. 1997;17(5):596–599. [PubMed: 9251876]
Andersson P-G, Dahl S, Hansen JH, Hansen PE, Hedman C, et al. Prophylactic treatment of classical and non-classical migraine with metropolol - a comparison with placebo. Cephalalgia. 1983;3:207–212. [PubMed: 6640652]
Kangasniemi P, Andersen AR, Andersson PG, et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia. 1987;7(4):231–238. [PubMed: 3322569]
Siniatchkin M, Andrasik F, Kropp P, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia. 2007 Sep;27(9):1024–1032. [PubMed: 17680819]
Ekbom K, Lundberg PO. Clinical trial of LB-46 (d, 1–4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in migraine prophylaxis. Headache. 1972;12(1):15–17. [PubMed: 4402287]
Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis. Acta. Neurol. Scand. 1972;48:124–128. [PubMed: 4401692]
Borgesen SE, Nielsen JL, Moller CE. Prophylactic treatment of migraine with propranolol. A clinical trial. Acta. Neurol. Scand. 1974;50(5):651–656. [PubMed: 4611129]
Dahlof C. No clearcut long-term prophylactic effect of one month treatment of propranolol with migraineurs. Cephalalgia. 1987;7(Suppl 6):459–460.
Diamond S, Kudrow L, Stevens J, Shapiro DB. Long-term study of propranolol in the treatment of migraine. Headache. 1982;22(6):268–271. [PubMed: 7174304]
Diener HC, Foh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia. 1996;16(6):441–447. [PubMed: 8902255]
Forssman B, Henriksson KG, Johannsson V, Lindvall L, Lundin H. Propranolol for migraine prophylaxis. Headache. 1976;16(5):238–245. [PubMed: 977330]
Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta. Neurol. Scand. 1986;73(4):423–427. [PubMed: 3727918]
Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurology India. 2000;48(3):223–226. [PubMed: 11025624]
Wideroe TE, Vigander T. Propranolol in the treatment of migraine. Br. Med. J. 1974;2(921):699–701. [PMC free article: PMC1611139] [PubMed: 4604977]
Pita E, Higueras A, Bolanos J, Perez N, Mundo A. Propranolol and migraine. A clinical trial. Archivos de Farmacologia y Toxicologia. 1977;3(3):273–278. [PubMed: 350168]
Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol - a comparison with placebo. Cephalalgia. 1987;7(Suppl 6):457–458.
Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9(4):247–253. [PubMed: 2692838]
Malvea BP, Gwon N, Graham JR. Propranolol prophylaxis of migraine. Headache. 1973;12(4):163–167. [PubMed: 4566216]
Ahuja GK, Verma AK. Propranolol in prophylaxis of migraine. Indian J. Med. Res. 1985;82:263–265. [PubMed: 3908306]
Borgesen SE. Treatment of migraine with propranolol. Postgrad. Med. J. 1976;52(SUPPL 4 0):163–165. [PubMed: 787958]
Diamond S, Medina J. Double-blind study of propranolol for migraine prophylaxis. Headache. 1976;16:24–27. [PubMed: 767299]
Fuller GN, Guiloff RJ. Propranolol in acute migraine: a controlled study. Cephalalgia. 1990;10(5):229–233. [PubMed: 2272092]
Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta. Neurol. Scand. 1986;73(5):490–492. [PubMed: 3524092]
Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch. Neurol. 1997;54(9):1141–1145. [PubMed: 9311358]
Nadelmann JW, Stevens J, Saper JR. Propranolol in the prophylaxis of migraine. Headache. 1986;26(4):175–182. [PubMed: 3519529]
Nair KG. A pilot study of the value of propranolol in migraine. J. Postgrad. Med. 1975;21(3):111–113. [PubMed: 1107526]
Palferman TG, Gibberd FB, Simmonds JP. Prophylactic propranolol in the treatment of headache. Br. J. Clin. Pract. 1983;37(1):28–29. [PubMed: 6340710]
Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology. 1972;22(4):366–369. [PubMed: 4552716]
Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache. 1991;31(5):333–340. [PubMed: 1830566]
Colombo M, de Franchis R, Tommasini M, Sangiovanni A, Dioguardi N. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial. Hepatology. 1989;9(3):433–438. [PubMed: 2563985]
Gatta A, Merkel C, Sacerdoti D, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. Digestion. 1987;37(1):22–28. [PubMed: 3301478]
Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology. 1986;6(6):1239–1243. [PubMed: 3539741]
Lo GH, Lai KH, Lee SD, Tsai YT, Lo KJ. Does propranolol maintain post-sclerotherapy variceal obliteration? A prospective randomized study. J. Gastroenterol. Hepatol. 1993;8(4):358–362. [PubMed: 8374092]
Sheen IS, Chen TY, Liaw YF. Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis. Liver. 1989;9(1):1–5. [PubMed: 2646504]
Jensen LS, Krarup N. Propranolol in prevention of rebleeding from oesophageal varices during the course of endoscopic sclerotherapy. Scandinavian Journal of Gastroenterology. 1989;24(3):339–345. [PubMed: 2660250]
Lebrec D, Nouel O, Bernuau J, Bouygues M, Rueff B, Benhamou JP. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet. 1981;1(8226):920–921. [PubMed: 6112329]
Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N. Engl. J. Med. 1981;305(23):1371–1374. [PubMed: 7029276]
Lebrec D, Poynard T, Bernuau J, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology. 1984;4(3):355–358. [PubMed: 6373547]
Burroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N. Engl. J. Med. 1983;309(25):1539–1542. [PubMed: 6361553]
el Tourabi H, el Amin AA, Shaheen M, Woda SA, Homeida M, Harron DW. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann. Trop. Med. Parasitol. 1994;88(5):493–500. [PubMed: 7979639]
Colombo M, Sangiovanni A, Tommasini MA, De FR. [Beta-blockers in the prophylaxis of recurrent hemorrhage in cirrhotic patients. Random multicentric study] Argomenti Gastroenterol Clin. 1990;3(2):93–100.
El Tourabi H, El Amin AA, Shaheen M, Woda SA, Homeida M, Harron DWG. Portal hypertension secondary to schistosomiasis: reduced mortality and rebleeding with propranolol. Medecine et Chirurgie Digestives. 1993;22(5):309–310.
Butler J, Khadim G, Belue R, et al. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J. Card. Fail. 2003 Jun;9(3):203–209. [PubMed: 12815570]
Galatius S, Gustafsson F, Atar D, Hildebrandt PR. Tolerability of (beta)-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure - A randomized comparison. Cardiology. 2004;102(3):160–165. [PubMed: 15334027]
van der Does R, Hauf-Zachariou U, Pfarr E, et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am. J. Cardiol. 1999;83(5):643–649. [PubMed: 10080412]
Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) Heart. 2007 Aug;93(8):968–973. [PMC free article: PMC1994413] [PubMed: 17237130]
Worz R, Reinhardt-Benmalek B, Foh M, Grotemeyer KH, Scharafinski HW. [Prevention of migraine using bisoprolol. Results of a double-blind study versus metoprolol] Fortschr. Med. 1992;110(14):268–272. [PubMed: 1351025]
Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 2007 Oct 15;100(8):1254–1262. [PubMed: 17920367]
Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. Journal of Clinical Hypertension. 2007 Nov;9(11):866–875. [PubMed: 17978594]
Magee L, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy [Systematic Review] Cochrane Database of Systematic Reviews. 2007;1:1. [PubMed: 12917933]
Anonymous. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomised trials in post-infarction patients. Eur. Heart J. 1988;9:8–16. [PubMed: 2894312]
Baber NS, Evans DW, Howitt G, et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. Br Heart J. 1980;44(1):96–100. [PMC free article: PMC482366] [PubMed: 7000100]
Shekelle P, Morton S, Atkinson S. Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness, Evidence Report Number 82. Rockville, MD: Agency for Healthcare Research and Quality; 2003. [PMC free article: PMC4781559] [PubMed: 14571595]
Del Sindaco D, Pulignano G, Cioffi G, et al. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. J Cardiovasc Med (Hagerstown) 2007 Sep;8(9):675–682. [PubMed: 17700396]
Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am. J. Cardiol. 2005;95(1):29–35. [PubMed: 15619390]
Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med. 2001;344(18):1358–1365. [PubMed: 11333992]
Bell DSH, Lukas MA, Holdbrook FK, Fowler MB. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Current Medical Research & Opinion. 2006;22(2):287–296. [PubMed: 16466600]
Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur. Heart J. 1992;13(1):28–32. [PubMed: 1533587]
Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2(8251):823–827. [PubMed: 6116950]
Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am. Heart J. 2005 Jan;149(1):159–167. [PubMed: 15660048]
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK47176


Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...